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INTRODUCTION TO PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, after Alzheimer’s disease. Prevalence in people older than age 60 is approximately 1.4%.[1, 2] PD is characterized by many motor and non-motor symptoms. It presents with a range of motor symptoms usually consisting of asymmetric bradykinesia, resting tremor, and
rigidity; postural instability may develop later in the course of the disease.[3, 4] However 'pre-motor' PD-a range of nonmotor symptoms, particularly sleep disorders, mood disorders, impaired sense of smell, and constipation may occur up
to 20 years before the onset of motor symptoms.[5] The clinical paradigm has shifted from PD being considered a pure
motor or movement disorder to being recognized as a systemic synucleinopathy with many motor and non-motor symptoms and signs. The etiology of PD is largely unknown, but a combination of genetic and environmental factors is postulated. Several genes have been associated with inherited and early onset form of PD (LRK1, PINK1, Parkin, and DJ-1)
but these represent only a small subset (10-15%) of all PD cases.[6] It is now known that PD can present with changes
in mood, sleep, behavior, cognition and autonomic function this can initiate referrals to psychiatric, general medicine,
geriatric, orthopedic and even rheumatology clinics, before neurological referral is considered. Etiology is multifactorial
and is thought to be related to multiple mechanisms. Factors associated with development or Parkinsonism include exposure to oxidant toxins (e.g. pesticides, MPTP), head trauma, manganese exposure, head trauma.
General Approach to Parkinson’s disease

Diagnosis of Parkinson’s disease

tion combined with clinicopathological correlation. In
subsequent studies it has been demonstrated to have up
to 90 % accuracy in diagnosing PD when diagnosed by
an experienced neurologist. This is a three step recommended strategy for diagnosis of Parkinson’s disease.

The diagnosis of PD remains primarily clinical. In 1988,
Gibb and Lees developed the Queen Square Brain Bank
(QSBB) criteria for PD, based on careful clinical observa-
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UK Queen Square Brain Bank Criteria for the diagnosis of Parkinson's disease[7]
Step 1: Diagnosis of a Parkinsonian Syndrome

•
•

Bradykinesia (slow to initiate voluntary movement with
progressively reduced speed and amplitude of repetitive
actions) and at least one of the following:
•
Muscular rigidity
•
Postural instability unrelated to primary visual,
cerebellar, vestibular or proprioceptive dysfunction
•
Resting tremor

palsy, cerebellar signs, early severe autonomic
involvement, Babinski's sign, early severe dementia
with disturbance of language, memory or praxis
Exposure to Neurotoxin
Presence of cerebral tumour or communicating
hydrocephalus on neuroimaging

Step 3: Supportive Criteria for Parkinson's Disease
Three or more of the following are required for the
diagnosis of definite Parkinson's disease
•
Unilateral onset
•
Rest tremor present
•
Progressive disorder
•
Persistent asymmetry primarily affecting the side
of initial onset
•
Excellent response to levodopa (70%–100%)
•
Severe levodopa-induced chorea
•
Levodopa response for more than 5 years
•
Clinical course of over 10 years

Step 2: Exclusion Criteria for Parkinson's Disease
History of:
•
Repeated strokes with stepwise progression
•
Repeated head injury
•
Antipsychotics or dopamine-depleting drugs
•
Definite encephalitis and/or oculogyric crisis on no
drug treatment
More than one affected relative (Note: this exclusion
•
criteria is usually ignored)
•
Sustained Remission
•
Negative response to large doses of levodopa (if
malabsorption excluded)
•
Strictly unilateral features after 3 years
•
Other neurological features: supranuclear gaze

Work up of Parkinsonism at Initial Presentation
In patients with a clear clinical diagnosis and no atypical
signs the physician may decide not to order blood tests or
neuroimaging studies. There is no definitive diagnostic
test for PD. These tests are performed to diagnose other
conditions that may present like Parkinson’s disease.

[9-11]
Parkinson’s disease Mimics
Once structural, infectious, toxic and metabolic causes of Parkinsonism have been excluded, the evaluating physician
must consider features of the patient’s history and physical examination that may suggest an alternative cause for the
symptoms. A diagnosis of idiopathic PD should be assumed only after ruling out PD mimics such as other tremor disorders, drug-induced Parkinsonism, vascular parkinsonism, normal pressure hydrocephalus and parkinsonism-plus conditions. The following table outlines features that may help in the differential diagnosis of these conditions:[3]
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Parkinson’s disease more likely

Alternative diagnosis more likely

Slow onset and progression of symptoms over months
and years
For example a 55 year old man presenting with slowly
progressive difficulty using left hand with a mild tremor
at rest over the past year

Sudden onset or rapid progression over days and weeks
should suggest an alternative diagnosis such as a
stroke, brain tumour or TB meningitis

Unilateral disease or significant asymmetry on signs
and symptoms in the beginning of the disease

Symmetrical onset more commonly is associated with other
Parkinsoniansyndromes such as Diffuse Lewy Body disease,
Multisystem Atrophy, Progressive Supranuclear Palsy etc.

Tremor:
Tremor usually involves extremities and, less commonly
the jaw. Head tremor is almost never present in
idiopathic PD. 25% of Parkinson’s patients may never
manifest a tremor. The classic tremor in Parkinson’s
disease is a slow resting (low frequency) pill-rolling
tremor best seen when the hands are at rest or while
the patient is walking.It decreases with activity and can
be suppressed temporarily by the patient. Re-emergent
tremor: Tremor tends to diminish at least temporarily
once the patient is asked to stretch out the arms and
may return as this becomes the new rest position.
Onset of tremor is generally unilateral and over time
may involve the other side

Tremor:
Enhanced physiologic tremor: Tremor related to anxiety
is present in outstretched hands and throughout the
range of motion. Benign essential tremor is more
prominent when the patient stretches out his hands as
it is predominantly a postural tremor. Benign essential
tremor often involves the head causing a side-to-side or
up/down tremor (a 'no-no' or ‘yes-yes’ tremor). ). It can
affect the voice, is worsened with activity and is often
familial. Parkinson’s plus syndromes are less likely to
have a tremor at presentation.

Responsive to Levodopa

Lack of robust response to Levodopa

Autonomic symptoms include urinary urgency, orthostasis

Early onset of multiple autonomic symptoms suggest
MSA

Bulbar involvement is possible

Predominant early bulbar signs suggest a Parkinson’s
Plus syndrome like PSP

Falls occur late after significant rigidity or bradykinesia
develop

Frequent falls early in the course of disease suggests a
Parkinson’s Plus syndrome like PSP

Non motor symptoms may include constipation, anosmia,
insomnia and depression.
Lack of eye movement restriction except there may be some
impairment of conjugate upgaze and convergence

Vertical gaze palsy in which initial abnormality is impairment of downgaze with intact oculocephalic maneuver
suggests PSP

Lack of early respiratory muscle compromise

Stridor/strangulated dysarthria suggests MSA
Chronic history of neuroleptic use or antiemetic use
suggests a medication induced parkinsonism
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Table 1
Neuroimaging in Parkinson’s disease and Parkinson’s Plus Syndromes

tant for the physician to partner with the patient and the
family to treat PD. It is important that the patient understands that the treatment will allow for many years of
very adequate function but that the disease is progressive and incurable. Any patient with social or functional
impairment should be initiated on treatment. Almost all
patients that present to a physician require some form
of treatment. The most obvious motor symptom for
many patients is tremor, which is socially distressing;
however the tremor often does not impair function if it
is not severe. Rigidity, bradykinesia and in later stages
postural instability are frequently greater sources of
functional impairment. [13]

In a patient with classic features of Parkinson’s disease,
and absence of red flags for atypical Parkinsonism,
neuroimaging is not indicated initially. If the patient
subsequently develops any atypical features, then brain
MRI without contrast can be considered [10, 12] Treatment
of Motor Symptoms in Parkinson’s disease PD is the
only common neurodegenerative condition in which
effective long-term treatment is readily available. Special care needs to be exercised in treating PD as both
under treatment and over treatment can worsen a
patient's condition and may even accelerate the
progression to disability. The key is to treat the patient
appropriately and not to under or over treat. This implies
a level of treatment that relieves symptoms to the point
that the patient has a fairly good quality of life. The
physician needs to explain to the patient early on that
PD is an incurable but treatable disease that will require
a lifelong patient-physician partnership. The objectives
of optimal treatment should be clearly explained. The
objectives should be to treatment to a point that the
patient is adequately functional and has a good quality
of life. The first step in managing PD is to determine
whether treatment is needed or not. It is important for
the physician to partner with the patient and the family
to treat PD. The treatment usually results in many years
of a productive and functional life. In many patients the
disease does progress and the symptoms become
refractory to the treatments. Patients with social or
functional impairment should be initiated on treatment
and almost all patients that present to a physician
require some form of treatment. The most obvious
motor symptom for many patients is tremor, which is
socially distressing; however the tremor often does not
impair function if it is not severe. Rigidity, bradykinesia
and in later stages postural instability are frequently
greater sources of functional impairment. [30] The first
step in managing a diagnosed case of PD is to determine whether treatment is needed or not. It is impor-
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Overview of Pharmacologic Therapy for Motor
Symptoms in Parkinson’s disease [9, 13-17]
Pharmacologic treatment options include: Carbidopa/
levodopa; sooner or later virtually all patients with PD
will require carbidopa/levodopa. Dopamine agonists
(although not as effective ascarbidopa/ levodopa, carry
an advantage of delaying motor fluctuations and dyskinesias, especially in younger patients) [35]. Monoamine
oxidase type B inhibitors (symptomatic improvement is
modest with these); these are rasagiline and
selegiline)[36]. Anticholinergics (eg procyclidine and
trihexyphenidyl). These predominantly improve the
tremor, drooling and urinary frequency. These are associated with many adverse effects, which may be
particularly severe in the elderly and include urinary
retention, constipation, blurred vision, dry mouth,
confusion, and orthostatic hypotension)[34,37]. Amantadine [38] may reduce dyskinesias very effectively and can
also help tremor and fatigue. COMT inhibitors
(entacapone, tolcapone)[39]; prolong the half-life of
carbidopa/levodopa and make it last longer and make it
more effective.
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Carbidopa/ levodop

bromocriptine, are still used in Pakistan but should be
avoided due to the associated high frequency of cardiac
valvular, peritoneal and pleural fibrosis. Common
adverse effects of dopamine agonists include: Sedation
(may be severe and cause sleep attacks that may be
sudden and severe enough to cause car accidents).
Confusion, disorientation, hallucinations, delusions,
psychosis and hallucinations. Postural hypotension and
nausea. Impulse control disorder; this can consist of
pathological gambling, hypersexuality, compulsive
eating, compulsive shopping, compulsive hobbying.

A variety of pharmacologic and non-pharmacologic
treatments are effective in treating PD. The cheapest
and the most effective medication is still
carbidopa/levodopa. Common adverse effects include
nausea and light headedness. In the past there was
concern about potential neurotoxicity and acceleration
of underlying disease associated with use of
carbidopa/levodopa but this concern has been laid to
rest. Recent studies reveal earlier use of
carbidopa/levodopa does not accelerate progression of
PD. Peak-dose dyskinesia (involuntary-dance like movements) may develop after several years of using
carbidopa/levodopa in younger patients and patients on
high doses. This is one reason why many neurologists
would prefer to avoid carbidopa/levodopa as first line
treatment in the younger (<60 years age) patient and
initiate treatment with a dopamine agonist and rasagiline instead. In individuals already on carbidopa/
levodopa, shortening the interdose interval and reducing individual doses may reduce the severity and even
postpone development of motor fluctuations and
complications [40]. In Pakistan the available formulation
of levodopa contains 250 mg levodopa in combination
with 25 mg of carbidopa. This may not be the optimal
formulation to be given in the earlier stages of PD.
Using a 25 carbidopa/100 levodopa formulation
(available as imported medicine) or quarter or half of
the 25/250 pill may be better.

Response to Treatment as Parkinson’s disease
Progresses
As PD progresses the response to treatment varies.
Early Parkinson's disease; The early stage of PD is also
called the “honeymoon period” when symptoms
respond well to a variety of treatments and there is a
sustained response to single doses of medications. [41]
Late Parkinson's disease; As PD progresses, the
response to dopamine therapy becomes less sustained,
probably as a consequence of the loss of dopaminergic
neurons. Motor fluctuations develop and the addition of
MAO-B inhibitors or COMT-inhibitors may then be
considered. These agents increase the potency of
levodopa and prolong its effect by inhibiting the metabolic breakdown of levodopa and increasing its
bio-availability. If given in combination with Carbidopa/
levodopa they help to decrease off-time and prolong the
on-time. MAO-B inhibitors include selegiline and
rasagiline. This class of drug produces modest symptomatic benefit but has not been shown to delay motor
complications. A rare adverse effect of selegiline but
not rasagiline is precipitation of a hypertensive crisis if
consumed with tyramine containing foods. COMTinhibitors includeentacapone and tolcapone. COMTinhibitors produce moderate improvement in motor
symptoms. Entacapone in combination with levodopa
shows minimal delay in onset of motor complications
(dyskinesia). Tolcapone comes with a black box warning
for fulminant liver failure, which may be fatal.

Dopamine Agonists
Dihydroergocryptine, pergolide, pramipexole, ropinirole,
piribedil, rotigotine, bromocriptine, cabergoline and
lisuride are the dopamine agonists used in PD. Ropinirole is the most widely available and frequently used
dopamine agonist in Pakistan. There is no particular
difference in efficacy between different dopamine
agonists, so physicians should familiarize themselves
with the dosage titration and potential adverse effect of
one of them. Ergot-based dopamine agonists, such as
Treatment of Parkinson’s disease based on Patient’s Age
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In patients older than 60 years of age who present with
symptoms, consider starting with carbidopa/levodopa
as it is more effective and generally better tolerated. In
younger patients (<60 years) it may be better to start
with one of the dopamine agonists in order to delay the

dyskinesias that may occur with Carbidopa/levodopa
therapy, particularly in the young PD patients. Eventually even the younger patients may require Carbidopa/
levodopa as the disease progresses and a more potent
medication is needed.

Table 1; Characteristics of commonly used medications for motor symptoms in PD [19]
Drug Class
Levodopa
Dopamine Agonists

Indication
First line therapy in patients over 60 years of age
First line therapy in younger patients
or add on to carbidopa/levodopa

Impact on Motor symptoms
Excellent
Moderate

MAO-B Inhibitors

First line for mild disease with depression.
Add on therapy for motor fluctuationsto carbidopa/levodopa

Limited

COMT inhibitors
Anticholinergics

Add on therapy for motor fluctuations
Limited use. Only improves PD tremor

Improves wearing off of Carbidopa/levodopa
Limited

Amantadine

Reduces dyskinesias and can improve
wearing off symptoms

Limited

Important Adverse Effects
Motor fluctuations Dyskinesia
Sedation/sleep attacks
Impulse control disorder
Pedal edema, Weight gain
Serotonin syndrome and
hypertensive crises may rarely occur
Narrow therapeutic window
Diarrhea
Confusion, Dry eyes/mouth
Urinary retention, Constipation
Confusion
Lividoreticularis
Pedal edema

Table 2 [3]
Relative Efficacy Profile
Factors affecting treatment choices

Levodopa

Dopamine Agonists

MAO-B Inhibitors

COMT Inhibitors

Efficacy on motor symptoms
Ease of Use
Risk of inducing motor complications

High
Low
High

Moderate
Moderate
Low

Low
Moderate
Low

Moderate
Low- Moderate
Low

Table 3 Relative Cost of Different Medications (as listed in Pharma guide 2014, electronic version)
Carbidopa/
levodopa
25/250 mg
Aptidopa
Dopasel
Meddopa
Neudopa
Sinedopa
Sinemet

Name of company

Price in PKR /tablet

Rasagiline 1 mg

Name of company

Price in PKR /tablet

Ropinirole
1 mg

Name of
company

Price in
PKR/tablet

aptcure
kurative
medera
Platinum
Valor/Al-Hameed
OBS

8
8
8
8
9
14.61

Alzilo
Rasagin

Searle
HiranisPharma

19.20
11.40

Amantadine 100 mg
Amantin
PK-Merz
Viofral

Name of company
Gene-Tech
Brookes
Biocare

Price in PKR /tablet
11.35
15.60
13.25

Propinol
Reol
Requip
Ronirol
Ropinol
XMG

Shrooq
Genome
GSK
Hilton
Amarant
Atco

9.50
16,66
34.28
21.19
24,33
12

Table 4
Titration Template for Commonly Used Medications for Motor Symptoms in Parkinson’s disease [19, 20]

Medication
Carbidopa/levodopa
Pramipexole

Start of titration
50 mg AM
3x0.088 mg

Weekly up-titration
50 mg Q3day
2nd week 3x0.18mg
3rd week 3x0.35mg
Then weekly 3x0.18 mg
2nd week 0.52 mg
3rd week 1.05 mg
4th week 2.1 mg
5th week 3.15 mg
Weekly 1mg
2 mg
2mg/24 hr
50 mg every 2 weeks

Pramipexole ER

0.25 mg AM

Ropinirole
Ropinirole ER
Rotigotine Patch
Piribedil
Selegiline
Rasagiline
Entacapone
Tolcapone

1 mg AM
2 mg AM
2mg/24h
50 mg HS
50 mg AM
100 mg AM

50 mg every 3 days

Amantadine

100 mg AM

100 mg q3days
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Maintenance dose
3-4 x 100 mg

Daily dose
300-800 mg

3x0.35-0.7 mg
1x 1.05-2.1 mg

1.05-3.3 mg
1.05-3.15 mg

3x 3-8 mg
6-24 mg
4-8 mg/24h
2-3 x 50 mg
5-10 mg
1 mg
3-4 x 100 mg
2-3 x 100 mg
at 6-12 hour intervals
1-3 x 100 mg

6-24 mg
6-24 mg
8-16 mg/24h
150-250 mg
5-10 mg
1 mg
600 mg
600 mg

-

MARCH

2015

100-400 mg

Deep Brain Stimulation in Parkinson’s disease

dopamine or underlying anxiety/ depression. Nocturia
may disturb the normal sleep pattern and may be due
to an over active bladder or an underlying sub-clinical
urinary tract infection.. Dopaminergic drug-wearing-off
may contribute to poor sleep and this may require a
bedtime dose of a long acting dopaminergic agent.
Restless legs syndrome is commonly associated with
Parkinson's disease and can be readily diagnosed and
treated. RLS presents with restlessness, pain, cramps
or vague discomfort in the legs upon rest, particularly
after laying down to sleep at night. The symptoms
improve upon movement, such as moving the legs or
getting up and walking, but symptoms often return once
the patient is recumbent again. RLS is associated with
involuntary leg movements as well, which can occur
during wakefulness or sleep. RLS symptoms should
trigger a search for underlying iron deficiency, which
should then be treated with iron replacement and
Vitamin C which may facilitate its absorption. If iron
deficiency is not present, RLS responds well to dopaminergic agonists such as ropinirole, typically administered 2 hours before bedtime. Gabapentin, pregabalin
and tramadol also are effective REM sleep behavior
disorder includes a variety of presentations wherein
patients may seem to be acting out dreams. Questioning
the family members may reveal the patient has been
talking in their sleep or even thrashing around and
acting out physical fights while asleep (which may result
in injuries). Always screen for REM sleep behavior disorder
as it is a treatable condition.[22-25] It is usually responsive
to a low dose of clonazepam.

[21]

Deep brain stimulation of the sub thalamic nucleus or
globus pallidus internum is used in the treatment of motor
symptoms of PD. There are multiple theories to suggest
the mechanism of action including a micro-lesioning
effect, resetting of aberrant pathways and circuits and
modulating excito-toxicity.
Deep brain stimulation of the subthalamic nucleus or globus
pallidum may be considered in the following situations.
•
•
•
•
•

Medication refractory disabling tremor.
Carbidopa/Levodopa responsive disease.
Motor fluctuations (on-off fluctuating motor symptoms
that require high doses of medications that need to be
given very frequently.
Disabling dyskinesias.
Patient does not have dementia or severe depression.

Axial and autonomic symptoms and freezing of the gait
usually does not get better with this surgery. The surgery
should only be done by high trained and experienced
Parkinson’s disease surgeons and after the surgery the
medications and the stimulator needs to be adjusted by
experienced Parkinson’s disease neurologists. It requires
life-long management by these teams and if not done and
managed properly can often make the condition of the
patient worse after the surgery.
Treatment of Non-Motor Symptoms in
Parkinson’s Disease

Depression And Anxiety:

Non-motor symptoms are a major contributor to impaired
quality of life of patients suffering from PD. [5] However,
these symptoms are often neglected during evaluation
and treatment. Non-motor symptoms are often easily
treatable, but lack of attention to them may make treatment of motor symptoms more difficult.[12] Non-motor
symptoms include behavioral symptoms like depression,
anxiety and psychosis, sleep disorders, dementia, dysautonomia (dysphagia, drooling, constipation, urinary
urgency and frequency, orthostatic hypotension) and
sensory symptoms (pain, Restless Legs Syndrome, numbness, joint stiffness in the limbs affected by the symptoms, etc). Non-motor symptoms can precede motor
symptoms by years.

Mood disorders are common in Parkinson's disease and
are frequently under-recognized and under-treated. PD
patients with depression may be difficult to motivate to
engage in regular exercise and in rehabilitation
programs. They also are more likely to be noncompliant
with treatment. Serotonin specific reuptake inhibitors
(SSRI's) often are effective in usual doses and can
greatly improve the quality of life of the patients.
Episodic shortness of breath and sweating are often
seen with advancing Parkinson's disease and may or
may not respond to dopaminergic medication. These
resemble panic attacks.[17,18]. Anxiety can be a nonmotor component of PD and although it perhaps most
often appears as a wearing off phenomenon, it also can
present as a more pervasive sense of anxiety in some
patients. It can often be treated by giving the dopaminergic
medications more frequently at lower doses.

Sleep Disorders:
These include rapid eye movement (REM) sleep behavi or
disorder (acting out dreams), insomnia, restless legs
syndrome (RLS), and poor sleep maintenance. Usually
the history provides the diagnostic clues needed to
address sleep issues. Insomnia can be related to lack of
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and correlates with the presence of subcortical and
cortical Lewy bodies. Environmental modifications are
the best tolerated interventions. Try to minimize
changes to routine, provide familiar things and memory
cues to minimize agitation.

may be helpful. Speech therapy is important along with
assessment of swallowing and advice regarding the
prevention of aspiration. Enteral feeding options
(short-term nasogastric tube or percutaneous endoscopic gastrostomy) may be needed in advanced cases.
[24]
. Eating pureed and soft foods with the head slightly
bent may be better and extra care with thin fluids like
water and tough foods like meat that are more likely to
cause dysphagia is important. Pills can be also be
crushed and administered with yogurt to facilitate
swallowing.

Discontinue potential aggravators:
Anticholinergics, amantadine, tricyclic antidepressants,
tolterodine and oxybutynin, benzodiazepines. If treatment
becomes necessary, the addition of a cholinesterase
inhibitor, such as rivastigmine, donepezil or galantamine
may be considered. Memantine also may be tried.[26, 27]

Orthostatic hypotension:
This is very important to recognize, prevent and treat as it
can cause dizziness, fainting spells and falls. This is
aggravated by volume depletion, diuretics, antihypertensive drugs, tricyclic antidepressants, nitrates and alphablockers used to treat prostatic hypertrophy. Dopaminergic drugs also may induce orthostatic hypotension. It
improves with increased salt intake. Elevating the headend of the bed at night (30–40°) may be helpful, as may
wearing of waist-high elastic-pressure stockings and/or
abdominal binders (if weather allows). Changing positions
slowly and exercises of the legs (leg crossing, toe raising,
and thigh contraction) before sitting up and standing can
help. If all of these are unsuccessful, medications, such
as midodrine or fludrocortisone, may be necessary. [25,26].
Domperidone can block the peripheral effect of the dopaminergic medications and can help as well.

Psychosis:
Symptoms of psychosis, such as hallucinations,
delusions, and illusions, are complications of therapy
and also may arise from the progression of the disease
process. When they occur, it is important to first correct
any metabolic abnormalities or fluid imbalance and to
treat any infection. It is important to minimize polypharmacy. Decreasing or stopping non-levodopa medications and optimizing levodopa can improve psychosis.
Antipsychotics may be needed, but those that are
potent dopamine depleting drugs can worsen Parkinsonism, especially the typical antipsychotics. Quetiapine is a sedating antipsychotic that does not appear to
worsen the motor symptoms of Parkinson's disease.
However as with other atypical antipsychotics, there
may be a small risk of cardiac complications and therefore
its use requires considering the risks and benefits for
each individual patient.

Constipation:
Constipation is a manifestation of general bradykinesia
and autonomic dysfunction in Parkinson’s disease. This
is a common problem aggravated by poor oral intake of
water/fiber. Bowel dysfunction has two components
decreased bowel movement frequency and difficulty
with the act of defecation. Decreased bowel movement
frequency results from slow colon transit and the
difficulty with the act of defecation is due to impaired
coordination and relaxation of the anorectal muscles.
Slow transit constipation often responds to increasing
water intake, fiber (ispaghula husk) and regular use of
Milk of Magnesia or lactulose. Defecatory dysfunction
usually does not respond to these interventions.

Urinary Urgency, Frequency and Nocturia:
These are common autonomic symptoms in PD. Recognizing and treating sub-clinical urinary tract infection is
very important. Initial treatment may involve reduced
intake of fluids after 6 pm and no caffeinated drinks
after 12 noon. If that is not sufficient, then anticholinergic medications may help. Anticholinergics that do not
cross the blood brain barrier are better, since these do
not worsen cognition. Tolterodine (2 mg twice daily) can
be considered for these symptoms. Botulinum toxin
type A injected in the detrusor muscle can also help but
is a very expensive form of treatment that should be
given only by trained physicians.[22,23]. For patients who
cannot tolerate medications, diapers and bedside
urinals should be available for patients.

Drooling:
Drooling is another common and distressing symptom.
Drooling is typically due to impairment of the swallowing
mechanism rather than overproduction of saliva and
may improve with chewing gum or sucking on honey or
ice. Drooling may require use of anticholinergic agents
or botulinum toxin injections into the salivary glands [19].

Dysphagia:
Multiple factors contribute to dysphagia in PD. Optimization
of motor control with dopamine replacement therapy
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However anticholinergics should generally be avoided in
the elderly patients and those with cognitive impairment
as they can result in confusion, hallucinations, blurring
of vision, constipation and urinary retention.

of motor and non-motor symptoms but also addressing
multiple areas of rehabilitation and improving the quality of
life of the individual as a whole. There is a significant role
for speech therapy, swallow evaluations, physical
therapy, exercise and gait training from the time of
diagnosis. Counseling patients and discussing possible
modifications to their life style and home set-up in
anticipation of expected disease progressionalsoare
important. There is increasing data to suggest that
exercise is neuroprotective for Parkinson’s disease, may
improve executive function and slow progression of
motor symptoms. SPARX trial and other smaller studies
show that exercise improves motor scores in patients
with Parkinson’s disease hence reducing falls and
improves quality of life.[31-44] Levodopa therapy is related
to increase homocystine due to its metabolism by COMT
enzyme. This theoretically increases the risk of stroke in
patients suffering from Parkinson’s treated with
levodopa. It might be reasonable to treat prophylactically with Vitamin B 12, folate, Vitamin B6.[45] Rehabilitation measures are focused towards improving mobility
and preventing fall-related morbidity. The team caring for
a PD patient should ideally be a combination of a physician, speech therapist, occupational therapist and
physical therapist.[13, 46, 47]

Pain and Dystonia:
Patients with PD suffer from pain related to multiple
pathogenic mechanisms, including central and peripherally mediated pain. Some of this may be related to
immobilization from bradykinesia or dystonia. Exercise,
physical therapy, pain management and botulinum
toxin injections for dystonia may improve the quality of
life of the patient.[28-30]
When to Refer to a Neurologist
Primary care providers can diagnose and treat Parkinsons
however consider referring to a neurologist if diagnosis is not
clear; difficulty in managing or complications with management; suboptimal response with management options
Importance of Multidisciplinary Care in the
Management of Parkinson’s disease
Effective management of PD not only includes management
Fall prevention in Parkinson’s Disease.

Gait Training: Take larger steps and make larger truns
Home modifications; - Imporve lighting. - Remove rugs and minimize clutter. - Avoid slippery surfaces
Careful selection of gait aid: Usually walker better than cane
Most Falls occur during Freezing: Use Laser pointers or visual cues to help re-initiate gait
Always consider an early referral to Physical medicine
Work closely with the family and care takers
[48, 49]
Resources and Support for Patients with Parkinson’s disease
There are many global patient education and advocacy forums where patients may be referred for information and
counseling.
Pakistan Parkinson's Society
American Parkinson’s Disease Association www.apdaparkinson.org
National Parkinson Foundation. www.parkinson.org
The Michael J. Fox Foundation for Parkinson's Research www.michaeljfox.org
World Parkinson Congress. www.pdf.org/world_parkinson_congress
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